YAP1 and neoplasm: Rho family of GTPase modulates actin cytoskeleton and positively controls YAP/TAZ activity.[15] Previous study suggested that mevalonate pathway also controls YAP and TAZ activation through Rho GTPase, which is independent of LATS1/2 kinases.[16] To further clarify the relationship between CSN6 regulated YAP activation and mevalonate metabolism, we then demonstrated that HMGCS1 overexpression can revert CSN6 KD‐mediated tumor growth inhibition in subcutaneous xenograft model (Figure 3F).